Published in Genome Med on July 28, 2010
A regularized Hotelling's T(2) test for pathway analysis in proteomic studies. J Am Stat Assoc (2011) 1.05
Genome-wide association study identified the human leukocyte antigen region as a novel locus for plasma beta-2 microglobulin. Hum Genet (2013) 0.84
Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases. Genome Med (2013) 0.82
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
β2-Microglobulin and TIMP1 Are Linked Together in Cardiorenal Remodeling and Failure. Cardiorenal Med (2014) 0.77
Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery. Front Biol (Beijing) (2012) 0.77
β2-microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease. J Am Heart Assoc (2014) 0.77
Application of proteomics to cerebrovascular disease. Electrophoresis (2012) 0.77
High levels of serum β2-microglobulin predict severity of coronary artery disease. BMC Cardiovasc Disord (2017) 0.75
Key Immune Events of the Pathomechanisms of Early Cardioembolic Stroke: Multi-Database Mining and Systems Biology Approach. Int J Mol Sci (2016) 0.75
Rationalising the role of Keratin 9 as a biomarker for Alzheimer's disease. Sci Rep (2016) 0.75
Plasma Retinol-Binding Protein 4 Levels and the Risk of Ischemic Stroke among Women. J Stroke Cerebrovasc Dis (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem (2003) 29.58
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
The KEGG database. Novartis Found Symp (2002) 6.86
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res (2006) 4.32
Mining the plasma proteome for cancer biomarkers. Nature (2008) 4.10
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol (1996) 3.82
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Alpha-1-acid glycoprotein. Biochim Biophys Acta (2000) 3.00
Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation (2007) 2.72
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med (2009) 2.24
Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res (2006) 2.10
Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res (2007) 2.04
Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest (1985) 1.54
The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol (2001) 1.52
Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab (2005) 1.31
The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) (2008) 1.28
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation (2007) 1.23
Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med (2004) 1.21
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21
Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke (2009) 1.19
Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med (2008) 1.19
Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab (2006) 1.15
Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med (2009) 1.07
Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med (2006) 1.04
Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis (2000) 0.93
Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J (1995) 0.89
Proteomics of beta2-microglobulin amyloid fibrils. Biochim Biophys Acta (2005) 0.88
Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects. Hypertens Res (2005) 0.88
Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev (2005) 0.85
Time course of alpha-1-acid glycoprotein and its relation to myocardial enzymes after acute myocardial infarction. Am J Cardiol (1985) 0.83
Serum amyloid A protein levels in haemodialysis patients. Nephrol Dial Transplant (1996) 0.79
Lipoprotein abnormalities in survivors of cerebral infarction with a special reference to apolipoproteins and triglyceride-rich lipoproteins. Atherosclerosis (1987) 0.77
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28
Genome-wide atlas of gene expression in the adult mouse brain. Nature (2006) 28.02
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol (2005) 11.00
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science (2002) 9.59
Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev (2003) 9.39
FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 9.24
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 8.95
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science (2009) 8.23
The case for early detection. Nat Rev Cancer (2003) 6.96
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Reconstructing genetic ancestry blocks in admixed individuals. Am J Hum Genet (2006) 5.92
The genome of a songbird. Nature (2010) 5.90
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Genome analysis of the platypus reveals unique signatures of evolution. Nature (2008) 5.74
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol (2002) 5.73
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Partial Correlation Estimation by Joint Sparse Regression Models. J Am Stat Assoc (2009) 5.41
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care (2006) 4.62
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Genome architectures revealed by tethered chromosome conformation capture and population-based modeling. Nat Biotechnol (2011) 4.56
DNA binding site sequence directs glucocorticoid receptor structure and activity. Science (2009) 4.48
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution. Nat Neurosci (2007) 4.28
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Mining the plasma proteome for cancer biomarkers. Nature (2008) 4.10
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 3.85
Comparative and demographic analysis of orang-utan genomes. Nature (2011) 3.83
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics (2007) 3.80
A burst of segmental duplications in the genome of the African great ape ancestor. Nature (2009) 3.63
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med (2004) 3.59
Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr (2005) 3.55
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol (2004) 3.53
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics (2006) 3.35
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
A suite of algorithms for the comprehensive analysis of complex protein mixtures using high-resolution LC-MS. Bioinformatics (2006) 3.32
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (2009) 3.14
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08